A new dawn for the use of thiazolidinediones in cancer therapy

Expert Opinion on Investigational Drugs

Volumn 23, Issue 4, 2014, Pages 501-510

  Joshi, Hardik ^a   Pal, Tanushree ^a   Ramaa, Cs ^a  

^a BHARATI VIDYAPEETH S COLLEGE OF PHARMACY   (India)

Author keywords

Anticancer; Repurposing; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; EFATUTAZONE; ERLOTINIB; GLITAZONE DERIVATIVE; IRS 5444; NETOGLITAZONE; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; DRUG MECHANISM; ENERGY METABOLISM; METASTASIS INHIBITION; METASTASIS POTENTIAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 84896105072     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.884708     Document Type: Review

References (66)

1. Bhatt AN, Mathur R, Farooque A, et al. Cancer biomarkers - current perspectives. Indian J Med Res 2010;132:129-49
2. Dueñas-González A, García-López P, Herrera LA, et al. The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer 2008;7:82
3. Sun G, Kashyap S. Cancer risk in type 2 diabetes mellitus: metabolic links and therapeutic considerations. J Nutr Metab 2011;2011:708183
4. Johnson J, Gale E. Diabetes, insulin use, and cancer risk: are observational studies part of the solution- or part of the problem? Diabetes 2010;59:1120-31
5. Bailey CJ, Day C. Thiazolidinediones today. Br J Diab Vasc Dis 2001;1:7-13
6. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diab Med 1999;16:179-92
7. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator- activated receptor gamma (PPAR gamma). J Biol Chem 1995;270:12953-6
8. Balkrishnan R, Arondekar BV, Camacho FT, et al. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in medicaidenrolled patients with type 2 diabetes mellitus. Clin Ther 2007;29:1306-15 (Pubitemid 351181207)
9. Beysen C, Murphy EJ, Nagaraja H, et al. A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes. J Lipid Res 2008;49:2657-63
10. de Vries CS, Russell-Jones DL. Rosiglitazone or pioglitazone in type 2 diabetes? BMJ 2009;339:b3076
11. Daniel K. The glitazones: proceed with caution. West J Med 2000;173(1):54-7
12. Jain V, Vora D, Ramaa CS. Thiazolidine-2,4-diones: progress towards multifarious applications. Bioorg Med Chem 2013;21(7):1599-620
13. Tyagi S, Gupta P, Saini A, et al. The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases. J Adv Pharm Technol Res 2011;2(4):236-40
14. Blanquicett C, Roman J, Michael Hart C. Thiazolidinediones as anti-cancer agents. Cancer Ther 2008;6(A):25-34
15. Sainis I, Vareli K, Karavasilis V, et al. PPARgamma: the portrait of a target ally to cancer chemo preventive agents. PPAR Res 2008;2008:436-89 .
16. Elrod HA, Sun SY. PPARgamma and apoptosis in cancer. PPAR Res 2008;2008:704165
17. Grillier-Vuissoz I, Mazerbourg S, Boisbrun M, et al. PPARgamma- independent activity of thiazolidinediones: a promising mechanism of action for new anticancer drugs? J Carcinogene Mutagene 2012;S8:1-15 .
18. Shiau CW, Yang CC, Kulp SK, et al. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Res 2005;65:1561-9 (Pubitemid 40270186)
19. Galli A, Mello T, Ceni E, et al. The potential of antidiabetic thiazolidinediones for anticancer therapy. Expert Opin Investig Drugs 2006;15(9):1040-9
20. Panigrahy D, Huang S, Kieran MW, et al. PPARgamma as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther 2005;4(7):687-93 (Pubitemid 41351164)
21. Colca JR, Tanis SP, McDonald WG, Kletzien RF. Insulin sensitizers in 2013: new insights for the development of novel therapeutic agents to treat metabolic diseases. Expert Opin Investig Drugs 2014;23(1):1-7
22. Oshizumi T, Ohta T, Ninomiya I, et al. Thiazolidinedione, a peroxisomeproliferator-activated receptorg ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. Int J Oncol 2004;25:631-9
23. Ohta T, Elnemr A, Yamamoto M, et al. Thiazolidinedione, a peroxisomeproliferator-activated receptorg ligand, modulates the E-cadherin/betacateninsystem in a human pancreatic cancer cell line, BxPC-3. Int J Oncol 2002;21:37-42
24. Veliceasa D, Schulze-Hoepfner FT, Volpert OV. PPARgamma and agonists against cancer: rational design of complementation treatments. PPAR Res 2008;2008:1-13
25. Omar HA, Salama SA, Arafa EA, et al. Antitumor effects of energy restrictionmimetic agents: thiazolidinediones. Bio Chem 2013;394(7):865-70 .
26. Kumagai T, Ikezoe T, Gui D, et al. RWJ-241947 (MCC-555), a unique peroxisome proliferator-activated receptor-gamma ligand with antitumor activity against human prostate cancer in vitro and in beige/nude/X-linked immunodeficient mice and enhancement of apoptosis in myeloma cells induced by arsenic trioxide. Clin Cancer Res 2004;10(4):1508-20 (Pubitemid 38365247)
27. Yamaguchi K, Lee SH, Eling TE, et al. A novel peroxisome proliferator-activated receptor gamma ligand, MCC-555, induces apoptosis via posttranscriptional regulation of NAG-1 in colorectal cancer cells. Mol Cancer Ther 2006;5(5):1352-61 (Pubitemid 43881329)
28. Min KW, Zhang X, Imchen T, et al. A peroxisome proliferator-activated receptor ligand MCC-555 imparts antiproliferative response in pancreatic cancer cells by PPARgamma-independent upregulation of KLF4. Toxicol Appl Pharmacol 2012;263(2):225-32
29. Weng JR, Chen CY, Pinzone JJ, et al. Beyond peroxisome proliferator-activated receptor gamma signaling: the multifacets of the antitumor effect of thiazolidinediones. Endocr Relat Cancer 2006;13(2):401-13 (Pubitemid 43886665)
30. Patil V, Tilekar K, Mehendale-Munj S, et al. Synthesis and primary cytotoxicity evaluation of new 5-benzylidene-2,4- thiazolidinedione derivatives. Eur J Med Chem 2010;45(10):4539-44
31. Mohan R, Sharma AK, Gupta S, et al. Design, synthesis, and biological evaluation of novel 2,4-thiazolidinedione derivatives as histone deacetylase inhibitors targeting liver cancer cell line. Med Chem Res 2012;21:1156-65
32. Skelhorne-Gross G, Nicol CJ. The key to unlocking the chemotherapeutic potential of PPARgamma ligands: having the right combination. PPAR Res 2012;2012:946943 .
33. Wei S, Yang J, Lee SL, et al. PPAR gamma-independent antitumor effects of thiazolidinediones. Cancer Lett 2009;276(2):119-24
34. Saha S, New LS, Han KH, et al. Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity. Toxicol Lett 2010;192:141-9
35. Choi J, Park Y, Lee et al. 1,3-Diphenyl- 1H-pyrazole derivatives as a new series of potent PPAR gamma partial agonists. Biorg Med Chem 2010;18:8315-23
36. Guasch L, Sala E, Castell-Auvi A, et al. Identification of PPAR gamma partial agonists of natural origin (I): development of a virtual screening procedure and in vitro validation. PLoS One 2012;7(11):e50816
37. Ohashi M, Oyama T, Putranto EW, et al. Design and synthesis of a series of alpha-benzyl phenylpropanoic acid-type peroxisome proliferator-activated receptor (PPAR) gamma partial agonists with improved aqueous solubility. Bioorg Med Chem 2013;21(8):2319-32
38. Grommes C, Karlo JC, Caprariello A, et al. The PPARgamma agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft model. Cancer Chemother Pharmacol 2013;71(4):929-36
39. Papi A, Tatenhorst L, Terwel D, et al. PPAR gamma and RXR gamma ligands act synergistically as potent antineoplastic agents in vitro and in vivo glioma models. J Neurochem 2009;109:1779-90
40. Rhodus N, Rohrer M, Pambuccian S, et al. Phase IIa chemoprevention clinical trial of pioglitazone for oral leukoplakia [Poster No. 945]. 89th General Session & Exhibition of the IADR; San Diego; 2011
41. Dragnev K, You M, Wang Y, et al. Lung cancer chemo prevention: difficulties, promise and potential agents? Expert Opin Investig Drugs 2013;22(1):35-47
42. He XX, Tu SM, Lee MH, et al. Thiazolidinediones and metformin associated withimproved survival of diabetic prostate cancer patients. Ann Oncol 2011;22:2640-5
43. Gottfried E, Rogenhofer S, Waibel H, et al. Pioglitazone modulates tumor cell metabolism and proliferation in multicellular tumor spheroids. Cancer Chemother Pharmacol 2011;67(1):117-26
44. Chen SW, Tsan YT, Chen JD, et al. Use of thiazolidinediones and the risk of colorectal cancer in patients with diabetes: a nationwide, population-based, case-control study. Diabetes Care 2013;36(2):369-75
45. Wei-Ping MA. Effects of pioglitazone combinated with radiotherapy on colon carcinoma xenograft in mice. Cancer Res Clin 2012;24(10):667-73
46. Jan HJ, Lee CC, Lin YM, et al. Rosiglitazone reduces cell invasiveness by inducing MKP-1 in human U87MG glioma cells. Cancer Lett 2009;277(2):141-8
47. Cellai I, Petrangolini G, Tortoreto M, et al. In vivo effects of rosiglitazone in a human neuroblastomaxenograft. Br J Cancer 2010;102(4):685-92
48. Sakharkar MK. Integrative approaches for drug discovery - PPAR gamma as a case study. Adv Biomed Infrastructure (Studies in Computational Intelligence) 2013;477:1
49. Arif IS, Hooper CL, Greco F, et al. Increasing doxorubicin activity against breast cancer cells using PPARgammaligands and by exploiting circadian rhythms. Br J Pharmacol 2013;169(5):1178-88
50. Jiang Y, Huang Y, Cheng C, et al. Combination of thiazolidinedione and hydralazine suppresses proliferation and induces apoptosis by PPARgamma upexpression in MDA-MB-231 cells. Exp Mol Pathol 2011;91(3):768-74
51. Miao R, Xu T, Liu L, et al. Rosiglitazone and retinoic acid inhibit proliferation and induce apoptosis in the HCT-15 human colorectal cancer cell line. Exp Ther Med 2011;2(3):413-17
52. Chiu SJ, Hsaio CH, Tseng HH, et al. Rosiglitazone enhances the radiosensitivity of p53-mutant HT- 29 human colorectal cancer cells. Biochem Biophys Res Commun 2010;394(3):774-9
53. Liu JJ, Hu T, Wu XY, et al. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone-induced apoptosis in leukemiak562 cells and its mechanismsof action. Int J Toxicol 2009;28(2):123-31
54. Liu JJ, Xu Y, Zhang Y, et al. Peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist rosiglitazone (RGZ) inhibits HL-60 cell growth by induction of apoptosis. Lab Medicine 2009;40:297-302
55. Liu JJ, Dai XJ, Xu Y, et al. Inhibition of lymphoma cell proliferation by peroxisomal proliferator-activated receptor-gamma ligands via Wnt signaling pathway. Cell Biochem Biophys 2012;62(1):19-27
56. Yan KH, Yao CJ, Chang HY, et al. The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells. Mol Carcinog 2010;49(3):235-46
57. Al-Alem L, Southard RC, Kilgore MW, et al. Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARgamma independent manner. Molecular and biomedical pharmacology faculty publications. PLoS One 2011;6(1):e16179
58. An Z, Liu X, Song H, et al. Effect of troglitazone on radiation sensitivity in cervix cancer cells. Radiat Oncol J 2012;30(2):78-87
59. Ban JO, Oh JH, Son SM, et al. Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NFkappaB via suppression of GSK-3beta expression. Cancer Biol Ther 2011;12(4):288-96
60. Copland JA, Marlow LA, Kurakata S, et al. Novel high-affinity PPAR gamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene 2006;25(16):2304-17
61. Shimazaki N, Togashi N, Hanai M, et al. Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumourxenografts and a syngeneic tumour implant model. Eur J Cancer 2008;44(12):1734-43
62. Su W, Necela BM, Fujiwara K, et al. The high affinity peroxisome proliferatoractivated receptor-gamma agonist RS5444 inhibits both initiation and progression of colon tumors in azoxymethane-treated mice. Int J Cancer 2008;123(5):991-7
63. Murakami H, Ono A, Shukuya T, et al. Durable response with oral PPARgamma agonist efatutazone (CS-7017) in a pretreated patient withadvanced thymic carcinoma. APLCC/ITMIG Abstr 2012;11(5):S422
64. Kim SW, Choi CM, Lee DH, et al. Phase Ib study of oral ppar gamma agonist efatutazone (cs-7017) in combination with erlotinibin korean patients with metastatic or unresectable locally advanced non-small cell lung cancer (NSCLC) who progressed after first-line therapy. APLCC/ITMIG Abstr 2012;11(5):S422
65. Pishvaian MJ, Marshall JL, Wagner AJ, et al. A phase I study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer 2012;118(21):5403-13
66. Smallridge RC, Copland JA, Brose MS, et al. Efatutazone, an oral PPAR-gamma agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase I trial. J Clin Endocrinol Metab 2013;98(6):2392-400